Didanosine

NOT RECOMMENDED AS AN ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.1. Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

EMLc | Codes ATC: J05AF02

Indication	Human immunodeficiency virus disease without mention of tuberculosis or malaria, clinical stage unspecified Code ICD11: 1C62.Z
INN	Didanosine
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	**Oral > Liquid:** 100 mg buffered powder for oral solution ; 167 mg buffered powder for oral solution ; 250 mg buffered powder for oral solution **Oral > Solid:** 25 mg buffered chewable dispersible tablet ; 50 mg buffered chewable dispersible tablet ; 100 mg buffered chewable dispersible tablet ; 150 mg buffered chewable dispersible tablet ; 200 mg buffered chewable dispersible tablet ; 125 mg unbuffered enteric coated capsule ; 200 mg unbuffered enteric coated capsule ; 250 mg unbuffered enteric coated capsule ; 400 mg unbuffered enteric coated capsule
Historique des statuts LME	Ajouté pour la première fois en 2002 (TRS 914) Modifié en 2007 (TRS 950) Retiré en 2015 (TRS 994)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets.
Wikipédia	Didanosine
DrugBank	Didanosine

Résumé des preuves et recommandation du comité d'experts

Didanosine was recommended for deletion from the EML and EMLc as it was not longer aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1). References: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.

